Clinical Trials
14
Active:1
Completed:7
Trial Phases
3 Phases
Phase 1:6
Phase 2:7
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (14 trials with phase data)โข Click on a phase to view related trials
Phase 2
7 (50.0%)Phase 1
6 (42.9%)Not Applicable
1 (7.1%)Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Revalesio Corporation
- Target Recruit Count
- 82
- Registration Number
- NCT04693715
- Locations
- ๐บ๐ธ
Northwestern University, Chicago, Illinois, United States
๐บ๐ธOregon Health & Science University, Portland, Oregon, United States
๐บ๐ธThe Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis
Phase 2
Not yet recruiting
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-12-09
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Revalesio Corporation
- Target Recruit Count
- 140
- Registration Number
- NCT02988297
Study of Electro-kinetically Modified Water for the Treatment of Pain Associated With Endometriosis
Not Applicable
Terminated
- Conditions
- Pelvic Pain
- First Posted Date
- 2015-08-14
- Last Posted Date
- 2018-01-25
- Lead Sponsor
- Revalesio Corporation
- Target Recruit Count
- 9
- Registration Number
- NCT02523794
- Locations
- ๐บ๐ธ
Madigan Army Medical Center, Tacoma, Washington, United States
Pilot Study of RNS60 in Allergen-induced Bronchoconstriction
- First Posted Date
- 2015-07-14
- Last Posted Date
- 2016-10-04
- Lead Sponsor
- Revalesio Corporation
- Registration Number
- NCT02497222
- Locations
- ๐บ๐ธ
Massachusetts General Hospital, Boston, Massachusetts, United States
Systemic Bioactivity of Inhaled Nebulized RNS60
Phase 1
Completed
- Conditions
- Systemic Bioactivity of Nebulized RNS60
- Interventions
- Drug: Normal saline
- First Posted Date
- 2015-07-07
- Last Posted Date
- 2015-09-22
- Lead Sponsor
- Revalesio Corporation
- Target Recruit Count
- 56
- Registration Number
- NCT02490865
- Locations
- ๐ฌ๐ง
Surrey Clinical Research Centre, Guildford, Surrey, United Kingdom
- Prev
- 1
- 2
- 3
- Next
News
No news found